VANCOUVER, British Columbia, April 21, 2021 (GLOBE NEWSWIRE) — Myconic Capital Corp. (previously, Auralite Investments Inc.) (CSE: MEDI) (FRA: MY0) (the “Firm” or “Myconic“) is happy to announce that, additional to its press launch of March 10, 2021, it has accomplished the acquisition of the entire issued and excellent fairness of Mindscape Ketamine & Infusions Remedy, PLLC (“Mindscape”) a psychological well being and ache clinic primarily based in Houston, Texas. In consequence, Myconic made a money fee of US$50,000 and issued 94,292 frequent shares of Myconic (the “Fee Shares”) to the only proprietor of Mindscape.
The Fee Shares are topic to a lockup interval of twelve months, with one third of the Fee Shares every being launched at intervals of 4, six, and twelve months following closing.
Mindscape Ketamine & Infusions Remedy, PLLC is a clinic in Houston, Texas, providing inexpensive supply of concierge IV ketamine remedy for treatment-resistant temper issues, psychological well being issues, and continual ache circumstances. Operated by Dr. Quang Henderson, a licensed Board-Licensed Emergency Doctor with over 20 years of expertise with ketamine, Mindscape assists individuals coping with melancholy, nervousness, PTSD, continual ache, and different temper issues utilizing the medical process of IV ketamine remedies in low dose, excessive dose, or non-public periods.
Mindscape is the one IV ketamine clinic in Houston to supply digital reality-based guided meditation to enrich IV ketamine infusions within the remedy of melancholy, bipolar dysfunction, nervousness, PTSD, OCD, and different temper issues.
Myconic Capital Corp is an funding issuer with a diversified portfolio that’s centered on rising firms energetic within the high-tech, actual property, hashish, mining and well being & wellness sectors.
On behalf of:
MYCONIC CAPITAL CORP.
CEO and Director
For additional data, please contact:
The Canadian Securities Trade (the “CSE”) has not reviewed and doesn’t settle for accountability for the accuracy or adequacy of this launch.
Discover Concerning Ahead Trying Data:
This information launch incorporates forward-looking statements together with statements concerning any of the Myconic holdings or investments, as properly different statements that aren’t historic information. Readers are cautioned to not place undue reliance on forward-looking statements, as there will be no assurance that the plans, intentions or expectations upon which they’re primarily based will happen. By their nature, forward-looking statements contain quite a few assumptions, recognized and unknown dangers and uncertainties, each common and particular, that contribute to the likelihood that the predictions, forecasts, projections and different forward-looking statements is not going to happen, which can trigger precise efficiency and ends in future durations to vary materially from any estimates or projections of future efficiency or outcomes expressed or implied by such forward-looking statements. These assumptions, dangers and uncertainties embrace, amongst different issues, the state of the financial system typically and capital markets specifically, investor curiosity within the enterprise and future prospects of the Firm.
The forward-looking statements contained on this information launch are made as of the date of this information launch. Besides as required by regulation, the Firm disclaims any intention and assumes no obligation to replace or revise any forward-looking statements, whether or not on account of new data, future occasions or in any other case, besides as required by relevant securities regulation. Moreover, the Firm undertakes no obligation to touch upon the expectations of, or statements made, by third events in respect of the issues mentioned above.